Look Towards A New Future

Jun 18, 2012

Genitourinary Drugs: Technologies and Global Markets

  • The total market for genitourinary drugs is projected to increase from $26.5 billion in 2011 to $30.7 billion in 2016 at a compound annual growth rate (CAGR) of 3% for a period of five years, from 2011 to 2016.
  • The market for hormonal contraceptives was $10.4 billion in 2010, which rose to more than $11 billion in 2011. This segment is further projected to reach $14.5 billion by 2016, a CAGR of 5.7% for a period of five years, 2011 to 2016.
  • The Benign Prostatic Hypertrophy (BPH) market was valued at $3.9 billion in 2010 and decreased to $3.5 billion in 2011. The market is projected to reach nearly $3.7 billion by 2016, a CAGR of 0.8% for a period of five years, 2011 to 2016.




This study provides a comprehensive analysis of the market for genitourinary drugs on a global basis. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends, in order to quantify and qualify the market for drug products to treat various genitourinary diseases in both men and women. Individual drug product-types are forecast on a global basis, as are overall disease segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.


For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute the strategy to capture profit from opportunity.

The genitourinary disease drug market presents a significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of genitourinary diseases and the pharmaceutical products for their treatment. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease category. Continued growth is expected in emerging geographies, driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.

Get your copy of this report @

Report Details:
Published: June 2012
No. of Pages: 198
Price: Single User License: US$ 4850  Corporate User License : US$8500


Current and projected product forecasts during the forecast period (2011 to 2016) are discussed. New product launches will be discussed. Revenue figures for 2010 are in an actual figure, except where actual results have not been reported due to the release timing of the report.

The report includes analysis of leading and emerging drug products for each genitourinary disease. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients with genitourinary diseases.

Market figures are based on revenues at the manufacturers’ level and are projected at 2011-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market

Included in this report are forecasts by product, product category and company from 2009 through 2016. The study is arranged to offer an overview of the genitourinary disease drug market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each drug subsegment.

Where possible, epidemiological data is presented to underscore the importance of these diseases in the world population and the potential morbidity/mortality resulting from ineffective treatment of these diseases worldwide. Patent and clinical trial information is reviewed for various drugs. The status of approvals of drugs in each disease segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

Diagnostics for each disease area and various drugs are described. However, diagnostics are not included in market figures, as they are outside of the scope of this report.

All market share data presented is on a global basis, unless specifically noted.


This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the genitourinary drug market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition (M&A) opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including the following.

Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development and R&D.

Emerging players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their product or technology as compared to leading, competitive and emerging products. In addition, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.

Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunities and risks that are being encountered in the industry, in a product and company specific analysis.

Equity analysts are provided detailed forecasts for the next five years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.


In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts and leading individuals in the field.

The genitourinary disease drug market comprises drugs for treatment of an assortment of specific diseases in both men and women. For completeness, the current and forecast markets comprise the total market opportunity for each respective segment. Within each subsection, there are detailed forecasts for each driving mechanism, or relevant area of growth.

Information to prepare this report was obtained from participating and emerging companies in the genitourinary disease area, the American Urology Association, the American Infertility Association, the National Institute of Kidney and Urological Disease (NIDDK, NIH), the National Library of Medicine (NLM, NIH) database and the U.S. Patent and Trademark Office (USPOTP). Additional information was obtained from a variety of medical and technical journals in the various specialties of the genitourinary diseases. Other sources included the New York Times, the Wall Street Journal, the Washington Post, other newspapers and company documents, and other internet websites. Population estimates are based on those reported by the International Database of the U.S. Census Bureau. Statistical data was obtained from the World Health Organization (WHO), the National Institute of Health (NIH) and the WHO Collaborating Centre for Drug Statistics Methodology (Norway).

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.